Differential effects of protein intake versus intake of a defined oligopeptide on FGF-21 in obese human subjects in vivo

Fangmann, Daniela; Geisler, Corinna; Schlicht, Kristina; Hartmann, Katharina; Köpke, Jana; Tiede, A; Settgast, Ute; Türk, Kathrin; Schulte, Dominik M.; Altmann, Karina; Clawin‐Rädecker, Ingrid; Lorenzen, Peter Christian; Schreiber, Stefan; Schwarz, Karin; Laudes, Matthias

doi:10.1016/j.clnu.2020.06.006

Cited by 6 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concerning other important factors related to the modulation of glucose levels, Fangmann et al 45 reported how the ingestion of casein or of a specific oligopeptide from casein has an in vivo impact on FGF-21 (which is a metabolic modulator implied in the decrease of glucose levels and improvement of insulin sensitivity without hypoglycaemia) in subjects with obesity ( n = 40, mean age of 41 years old) in a randomized double-blind cross-over design for 20 weeks (8 of intervention, 4 wash-out, 8 of intervention). The results showed that the concentration of FGF-21 was decreased in these patients with obesity without T2DM after ingesting the protein, but not in the ones suffering from the disease.…”

Section: Description Of Resultsmentioning

confidence: 99%

Protein-based nutritional strategies to manage the development of diabetes: evidence and challenges in human studies

Montserrat-de la Paz,

D. Miguel-Albarreal,

Gonzalez-de la Rosa

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Description Of Resultsmentioning

confidence: 99%

Protein-based nutritional strategies to manage the development of diabetes: evidence and challenges in human studies

Montserrat-de la Paz,

D. Miguel-Albarreal,

Gonzalez-de la Rosa

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

“…with an increase in the insulin sensitivity index by 20% . In obese patients, oral supplementation of 0.5 g of β-casein hydrolysate in whey drink for 8 weeks could increase the serum concentration of fibroblast growth factor 21 (FGF-21), a metabolic regulator in lowering glucose and improving insulin sensitivity . In addition, several studies showed that protein hydrolysates with high amounts of peptides could also exhibit an antidiabetic effect.…”

Section: Effects Of Bioactive Peptides In In Vitro Studiesmentioning

confidence: 99%

“…238 In obese patients, oral supplementation of 0.5 g of β-casein hydrolysate in whey drink for 8 weeks could increase the serum concentration of fibroblast growth factor 21 (FGF-21), a metabolic regulator in lowering glucose and improving insulin sensitivity. 239 In addition, several studies showed that protein hydrolysates with high amounts of peptides could also exhibit an antidiabetic effect. Consumption of 500 mg enzymatic hydrolysate from Styela clava flesh tissue hydrolysate daily for 4 weeks significantly decreased glycated hemoglobin (HbA 1C ) levels by 2.7% (p < 0.05) compared with the basal level in diabetic patients.…”

Section: Modulation Of Glucose and Lipid Metabolism In Hepatocytesmentioning

confidence: 99%

Production of Food-Derived Bioactive Peptides with Potential Application in the Management of Diabetes and Obesity: A Review

Wang

Yang

et al. 2023

J. Agric. Food Chem.

View full text Add to dashboard Cite

The prevalence of diabetes mellitus and obesity is increasing worldwide. Bioactive peptides are naturally present in foods or in food-derived proteins. Recent research has shown that these bioactive peptides have an array of possible health benefits in the management of diabetes and obesity. First, this review will summarize the top-down and bottom-up production methods of the bioactive peptides from different protein sources. Second, the digestibility, bioavailability, and metabolic fate of the bioactive peptides are discussed. Last, the present review will discuss and explore the mechanisms by which these bioactive peptides help against obesity and diabetes based on in vitro and in vivo studies. Although several clinical studies have demonstrated that bioactive peptides are beneficial in alleviating diabetes and obesity, more double-blind randomized controlled trials are needed in the future. This review has provided novel insights into the potential of food-derived bioactive peptides as functional foods or nutraceuticals to manage obesity and diabetes.

show abstract

“…Data from the FoCus cohort were used to address several different research questions to date, relating to, e.g., diabetes and microbiome [ 32 – 34 ], microbiome association studies [ 35 ], multiple sclerosis [ 36 ], hypertension and genome wide association studies [ 37 – 40 ] in national and international consortia as well as in small more specific research [ 41 – 47 ] and intervention studies [ 48 ] (see Table S4).…”

Section: Baseline Characteristics Of the Study Populationmentioning

confidence: 99%

“…There was no effect on inflammation, but the serum level of fibroblast growth factor 21 (FGF-21) which is associated with beneficial effects (e.g. glucose-lowering and improvement of insulin sensitivity) was increased in the verum group [ 48 ].…”

Section: Baseline Characteristics Of the Study Populationmentioning

confidence: 99%

Cohort profile: the Food Chain Plus (FoCus) cohort

et al. 2022

Self Cite

View full text Add to dashboard Cite

The Food Chain Plus (FoCus) cohort was launched in 2011 for population-based research related to metabolic inflammation. To characterize this novel pathology in a comprehensive manner, data collection included multiple omics layers such as phenomics, microbiomics, metabolomics, genomics, and metagenomics as well as nutrition profiling, taste perception phenotyping and social network analysis. The cohort was set-up to represent a Northern German population of the Kiel region. Two-step recruitment included the randomised enrolment of participants via residents’ registration offices and via the Obesity Outpatient Centre of the University Medical Center Schleswig–Holstein (UKSH). Hence, both a population- and metabolic inflammation- based cohort was created. In total, 1795 individuals were analysed at baseline. Baseline data collection took place between 2011 and 2014, including 63% females and 37% males with an age range of 18–83 years. The median age of all participants was 52.0 years [IQR: 42.5; 63.0 years] and the median baseline BMI in the study population was 27.7 kg/m2 [IQR: 23.7; 35.9 kg/m2]. In the baseline cohort, 14.1% of participants had type 2 diabetes mellitus, which was more prevalent in the subjects of the metabolic inflammation group (MIG; 31.8%). Follow-up for the assessment of disease progression, as well as the onset of new diseases with changes in subject’s phenotype, diet or lifestyle factors is planned every 5 years. The first follow-up period was finished in 2020 and included 820 subjects.

show abstract

Differential effects of protein intake versus intake of a defined oligopeptide on FGF-21 in obese human subjects in vivo

Cited by 6 publications

References 45 publications

Protein-based nutritional strategies to manage the development of diabetes: evidence and challenges in human studies

Protein-based nutritional strategies to manage the development of diabetes: evidence and challenges in human studies

Production of Food-Derived Bioactive Peptides with Potential Application in the Management of Diabetes and Obesity: A Review

Cohort profile: the Food Chain Plus (FoCus) cohort

Contact Info

Product

Resources

About